FDA Approves Masimo Corporation’s Rad-G with Temperature Monitoring System

Trending News ☀️

Masimo Corporation ($NASDAQ:MASI) has just received clearance from the FDA for their Rad-G Temperature monitoring system. This is a major breakthrough for the company, as it brings their innovative technology to the forefront of patient monitoring systems. Masimo Corporation is a global medical technology company focused on improving patient outcomes and reducing costs of care. The company designs, manufactures, and markets a wide range of noninvasive patient monitoring products, including sensors and pulse oximeters. Their goal is to improve patient safety and satisfaction by providing accurate, reliable, and cost-effective monitoring solutions.

The Rad-G Temperature device monitors patient temperature without contact, making it an ideal solution for hospitals, doctor’s offices, and other healthcare settings. It is designed to reduce the risk of cross-contamination, as well as provide accurate temperature readings. This device is the first of its kind and has the potential to revolutionize patient monitoring. With FDA approval, Masimo Corporation can now bring their cutting-edge technology to the healthcare industry and is well-poised to shape the future of patient monitoring.

Price History

This approval is a major milestone for the company, as it opens up a whole new realm of possibilities for them in the medical technology sector. The approval of the Rad-G system allows MASIMO CORPORATION to offer a new product that provides unprecedented accuracy in temperature monitoring, while also providing a simple, efficient, and cost-effective solution. This will allow healthcare providers to more efficiently and more accurately monitor patient temperatures.

In reaction to the news of their approval, MASIMO CORPORATION’s stock opened at $193.0 and closed at $192.1, down by 0.1% from last closing price of 192.2. Although there was a slight dip in the stock price, this approval is likely to have a positive impact on the company’s long-term prospects. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Masimo Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Masimo Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Masimo Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Masimo Corporation are shown below. More…

Analysis

At GoodWhale, we help investors make informed decisions about their investments with our comprehensive and easy-to-use financial analysis tools. We recently conducted a financial analysis of MASIMO CORPORATION and found that it is a high risk investment in terms of financial and business aspect. Our Risk Rating system detected 4 risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. To get a better idea of the risks associated with this investment, we encourage you to check out our website and register on GoodWhale.com. Once you’re registered, you can take a deep dive into the MASIMO CORPORATION’s financials and get a better understanding of the risks. We believe that understanding the risks is essential to making informed decisions when it comes to your investments. At GoodWhale, we make it our mission to help investors keep their finances safe. With our financial analysis tools, you can make sure you are always making the best decisions for your investments. Try out GoodWhale now and see for yourself! More…

Peers

In the medical device industry, there is intense competition between Masimo Corp and its rivals Elekta AB, Essilorluxottica, and Compumedics Ltd. While all four companies offer innovative products and services, each has its own unique strengths and weaknesses. As a result, the competition between them is fierce, and it is often difficult for one company to gain a significant advantage over the others.

– Elekta AB ($OTCPK:EKTAY)

Despite a challenging year for the company, Elekta’s market cap has grown to 2.09B as of 2022. This is due in part to the company’s strong return on equity, which stands at 11.86%. Elekta is a leading provider of radiation therapy solutions for the treatment of cancer. The company’s products are used in over 6,000 hospitals and clinics around the world, and its solutions are backed by a team of over 3,000 employees.

– Essilorluxottica ($LTS:0OMK)

EssilorLuxottica is a French-Italian multinational corporation that designs, manufactures, and markets ophthalmic lenses, instruments, and equipment. The company has a presence in over 130 countries and employs more than 140,000 people. The company was formed in 2018 through the merger of Essilor International and Luxottica.

– Compumedics Ltd ($ASX:CMP)

Computedics Ltd is a technology company that provides computing and analytics solutions. The company has a market cap of 42.52M as of 2022 and a Return on Equity of 1.53%. Computedics Ltd provides computing and analytics solutions to businesses and organizations worldwide. The company offers a range of services, including data storage, cloud computing, data analysis, and security. Computedics Ltd is headquartered in Sydney, Australia.

Summary

MASIMO Corporation is an excellent investment opportunity for those looking for a profitable return. The company has recently received FDA clearance for its Rad-G with Temperature device, showing the company’s commitment to innovation and dedication to creating quality products. All of these factors make MASIMO Corporation a strong investment choice for investors.